A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer

Oncotarget

Volumn 7, Issue 28, 2016, Pages 43199-43219

  Kinzel, Linda ^a   Ernst, Anne ^a   Orth, Michael ^a   Albrecht, Valerie ^a   Hennel, Roman ^a   Brix, Nikko ^a   Frey, Benjamin ^b   Gaipl, Udo S ^b   Zuchtriegel, Gabriele ^c   Reichel, Christoph A ^c   Blutke, Andreas ^a   Schilling, Daniela ^d   Multhoff, Gabriele ^d   Li, Minglun ^a   Niyazi, Maximilian ^a   Friedl, Anna A ^a   Winssinger, Nicolas ^e   Belka, Claus ^a   Lauber, Kirsten ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cell death; Colorectal cancer; DNA damage response; HSP90 inhibition; Radiosensitization

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CASPASE; CHAPERONE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE; PROTEIN P53; MACROLIDE; RADICICOL; RADIOSENSITIZING AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CHROMATIN CONDENSATION; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LIVER TOXICITY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; BAGG ALBINO MOUSE; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; CHEMORADIOTHERAPY; COLORECTAL TUMOR; DNA REPAIR; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; HCT 116 CELL LINE; HUMAN; LIVER; LIVER CELL; LIVER FUNCTION TEST; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA REPAIR; FEMALE; HCT116 CELLS; HEPATOCYTES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIVER; LIVER FUNCTION TESTS; MACROLIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PRIMARY CELL CULTURE; PROTEOLYSIS; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978722259     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9774     Document Type: Article

References (80)

1. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10: 537-549
2. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clinical cancer research. 2012; 18: 64-76
3. Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H, Belka C. Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. Cancer letters. 2015; 368:209-29. doi: 10.1016/j.canlet.2015.02.047
4. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91: 8324-8328
5. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, Neckers LM. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell stress & chaperones. 1998; 3: 100-108
6. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, et al. NVPAUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008; 68: 2850-2860
7. Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget. 2014; 5: 2372-2389. doi: 10.18632/oncotarget.1706
8. Nagaraju GP, Alese OB, Landry J, Diaz R, El-Rayes BF. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FUbased chemotherapy. Oncotarget. 2014; 5: 9980-9991. doi: 10.18632/oncotarget.2484
9. Powers MV, Valenti M, Miranda S, Maloney A, Eccles SA, Thomas G, Clarke PA, Workman P. Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget. 2013; 4: 1963-1975. doi: 10.18632/oncotarget.1419
10. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. The Lancet Oncology. 2013; 14: e358-369
11. Sharma K, Vabulas RM, Macek B, Pinkert S, Cox J, Mann M, Hartl FU. Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response. Molecular & cellular proteomics. 2012; 11: M111 014654
12. Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clinical cancer research. 2007; 13: 4326-4330
13. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res. 2006; 66: 9211-9220
14. Schilling D, Kuhnel A, Konrad S, TetzlaffF, Bayer C, Yaglom J, MulthoffG. Sensitizing tumor cells to radiation by targeting the heat shock response. Cancer letters. 2015; 360: 294-301
15. Stingl L, Stuhmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. British journal of cancer. 2010; 102: 1578-1591
16. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003; 63: 8984-8995
17. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clinical cancer research. 2004; 10: 8077-8084
18. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. International journal of cancer. 2010; 126: 1216-1225
19. Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PloS one. 2012; 7: e35436
20. Barluenga S, Fontaine JG, Wang C, Aouadi K, Chen R, Beebe K, Neckers L, Winssinger N. Inhibition of HSP90 with pochoximes: SAR and structure-based insights. Chembiochem. 2009; 10: 2753-2759
21. Barluenga S, Wang C, Fontaine JG, Aouadi K, Beebe K, Tsutsumi S, Neckers L, Winssinger N. Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angewandte Chemie. 2008; 47: 4432-4435
22. Wang C, Barluenga S, Koripelly GK, Fontaine JG, Chen R, Yu JC, Shen X, Chabala JC, Heck JV, Rubenstein A, Winssinger N. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors. Bioorganic & medicinal chemistry letters. 2009; 19: 3836-3840
23. Karthikeyan G, Zambaldo C, Barluenga S, Zoete V, Karplus M, Winssinger N. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors. Chemistry. 2012; 18: 8978-8986
24. van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RG, van den Broek CB, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CA, Henning G, Gore-Booth J, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. European journal of cancer. 2014; 50: 1 e1-1 e34
25. Glimelius B. Radiotherapy in rectal cancer. British medical bulletin. 2002; 64: 141-157
26. Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS. Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? The cancer journal from Scientific American. 1999; 5: 242-247
27. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia. 2012; 14: 670-677
28. Annamalai B, Liu X, Gopal U, Isaacs JS. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Molecular cancer research. 2009; 7: 1021-1032
29. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2005; 65: 10686-10691
30. Schilling D, Bayer C, Li W, Molls M, Vaupel P, MulthoffG. Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1alpha. PloS one. 2012; 7: e31110
31. Cysyk RL, Parker RJ, Barchi JJ, Jr., Steeg PS, Hartman NR, Strong JM. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chemical research in toxicology. 2006; 19: 376-381
32. Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, Shirai M, Kubota N. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer science. 2005; 96: 911-917
33. Niyazi M, Belka C. Isobologram analysis of triple therapies. Radiat Oncol. 2006; 1: 39
34. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation. 1984; 22: 27-55
35. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015; 22: 58-73
36. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012; 19: 107-120
37. Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol. 2012; 2: 116
38. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, Vandenabeele P. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell death & disease. 2012; 3: e437
39. Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015; 22: 1071-1080
40. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997; 385: 637-640
41. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. The Journal of clinical investigation. 1999; 104: 263-269
42. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000; 290: 989-992
43. Mondal S, Bhattacharya K, Mallick A, Sangwan R, Mandal C. Bak compensated for Bax in p53-null cells to release cytochrome c for the initiation of mitochondrial signaling during Withanolide D-induced apoptosis. PloS one. 2012; 7: e34277
44. Hemmati PG, Guner D, Gillissen B, Wendt J, von Haefen C, Chinnadurai G, Dorken B, Daniel PT. Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene. 2006; 25: 6582-6594
45. Jacobsen AV, Lowes KN, Tanzer MC, Lucet IS, Hildebrand JM, Petrie EJ, van Delft MF, Liu Z, Conos SA, Zhang JG, Huang DC, Silke J, Lessene G, Murphy JM. HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. Cell death & disease. 2016; 7: e2051
46. Wang B, Chen Z, Yu F, Chen Q, Tian Y, Ma S, Wang T, Liu X. Hsp90 regulates autophagy and plays a role in cancer therapy. Tumour Biol. 2016; 37: 1-6
47. Zhao XM, Chen Z, Zhao JB, Zhang PP, Pu YF, Jiang SH, Hou JJ, Cui YM, Jia XL, Zhang SQ. Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis. Cell death & disease. 2016; 7: e2089
48. Franken NA, Oei AL, Kok HP, Rodermond HM, Sminia P, Crezee J, Stalpers LJ, Barendsen GW. Cell survival and radiosensitisation: modulation of the linear and quadratic parameters of the LQ model (Review). Int J Oncol. 2013; 42: 1501-1515
49. Spiegelberg D, Dascalu A, Mortensen AC, Abramenkovs A, Kuku G, Nestor M, Stenerlow B. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells. Oncotarget. 2015; 6: 35652-35666. doi: 10.18632/oncotarget.5363
50. Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF, Kasibhatla SR. Orally active purine-based inhibitors of the heat shock protein 90. Journal of medicinal chemistry. 2006; 49: 817-828
51. He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. Journal of medicinal chemistry. 2006; 49: 381-390
52. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003; 425: 407-410
53. Barrott JJ, Hughes PF, Osada T, Yang XY, Hartman ZC, Loiselle DR, Spector NL, Neckers L, Rajaram N, Hu F, Ramanujam N, Vaidyanathan G, Zalutsky MR, Lyerly HK, Haystead TA. Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chemistry & biology. 2013; 20: 1187-1197
54. Egorin MJ, Rosen DM, WolffJH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998; 58: 2385-2396
55. Guo W, Reigan P, Siegel D, Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug metabolism and disposition: the biological fate of chemicals. 2008; 36: 2050-2057
56. Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90-targeted therapy. Current molecular medicine. 2012; 12: 1125-1141
57. Ernst A, Anders H, Kapfhammer H, Orth M, Hennel R, Seidl K, Winssinger N, Belka C, Unkel S, Lauber K. HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer letters. 2015; 365: 211-222
58. Sugimoto K, Sasaki M, Isobe Y, Tsutsui M, Suto H, Ando J, Tamayose K, Ando M, Oshimi K. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene. 2008; 27: 3091-3101
59. Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N, Ando K, Okayasu R. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun. 2006; 351: 658-663
60. He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Investigational new drugs. 2014; 32: 577-586
61. Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008; 27: 5567-5577
62. Fujii Y, Kato T, Kubota N, Fujimori A, Niwa O, Okayasu R. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Oncology reports. 2010; 23: 199-203
63. Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol. 2006; 29: 1111-1117
64. McNamara AV, Barclay M, Watson AJ, Jenkins JR. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins. Biochem Pharmacol. 2012; 83: 355-367
65. Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis. 2012; 27: 211-218
66. Flinterman M, Guelen L, Ezzati-Nik S, Killick R, Melino G, Tominaga K, Mymryk JS, Gaken J, Tavassoli M. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem. 2005; 280: 5945-5959
67. Cai Y, Qiu S, Gao X, Gu SZ, Liu ZJ. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Apoptosis. 2012; 17: 777-783
68. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC. Rational design of shepherdin, a novel anticancer agent. Cancer cell. 2005; 7: 457-468
69. Bazan V, Agnese V, Corsale S, Calo V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A, Gruppo Oncologico dell'Italia M. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Annals of oncology. 2005; 16 Suppl 4: iv50-55
70. Li YP, Chen JJ, Shen JJ, Cui J, Wu LZ, Wang Z, Li ZR. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells. Cancer chemotherapy and pharmacology. 2015; 75: 773-782
71. Ambade A, Catalano D, Lim A, Mandrekar P. Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice. Hepatology. 2012; 55: 1585-1595
72. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282: 1497-1501
73. Hennel R, Brix N, Seidl K, Ernst A, Scheithauer H, Belka C, Lauber K. Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated gamma-irradiation. Radiat Oncol. 2014; 9: 85
74. Peter C, Waibel M, Keppeler H, Lehmann R, Xu G, Halama A, Adamski J, Schulze-OsthoffK, Wesselborg S, Lauber K. Release of lysophospholipid 'find-me' signals during apoptosis requires the ATP-binding cassette transporter A1. Autoimmunity. 2012; 45: 568-573
75. Lauber K, Appel HA, Schlosser SF, Gregor M, Schulze-OsthoffK, Wesselborg S. The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. J Biol Chem. 2001; 276: 29772-29781
76. Wagner BJ, Lindau D, Ripper D, Stierhof YD, Glatzle J, Witte M, Beck H, Keppeler H, Lauber K, Rammensee HG, Konigsrainer A. Phagocytosis of dying tumor cells by human peritoneal mesothelial cells. J Cell Sci. 2011; 124: 1644-1654
77. Harre U, Keppeler H, Ipseiz N, Derer A, Poller K, Aigner M, Schett G, Herrmann M, Lauber K. Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity. 2012; 45: 612-619
78. Werthmoller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide-and T-cell-dependent manner. Cell death & disease. 2015; 6: e1761
79. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. Journal of surgical oncology. 1986; 31: 229-234
80. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. European journal of biochemistry. 1981; 115: 207-216